Connect your AI

Journey Medical Corporation DERM Price / book

Price / book at other companies

Cumberland PharmaceuticalsCPIX

2.2×+0.2×

PTH

Pelthos Therapeutics Inc.PTHS

2×—

Arcutis Biotherapeutics, Inc.ARQT

15.4×+2.4×

HRO

HarrowHROW

45.7×+28.9×

Catalyst PharmaceuticalCPRX

3×-0.7×

Mirum Pharmaceuticals, Inc.MIRM

23×+13.5×

Other financials

Income statement

Revenue$16.0M+21.5%

Gross profit$9.7M+16.7%

Operating income-$1.5M+55.1%

Net income-$2.2M+45.2%

EPS (diluted)-$0.08+55.6%

Balance sheet

Cash & equivalents$27.2M+29.2%

Total debt$25.5M+1.2%

Total equity$30.8M+43.1%

Total assets$91.5M+7.7%

Cash flow

Operating cash flow$2.9M+203%

CapEx$3.8M—

Free cash flow-$6.0M—

Valuation

Market cap$194.94M+20.9%

Enterprise value$193.19M+16.2%

P/S3×+0.2×

Profitability

Gross margin65.4%-1.0pp

Operating margin-9.8%—

Net margin-14.8%—

FCF margin-43%—

Returns & leverage

Return on equity-36.6%—

Debt / equity0.8×-0.3×

Current ratio1.7×+0.4×

Where this comes from

Calculated from Journey Medical Corporation’s reported figures.

market cap/total stockholders equity=4.2×

Based on the most recent quarter.

The official record: Journey Medical Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Journey Medical Corporation's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Journey Medical Corporation's price / book?: Journey Medical Corporation (DERM) reported price / book of 4.2× in Q1 2026.
How has Journey Medical Corporation's price / book changed year-over-year?: Journey Medical Corporation's price / book decreased by 34.3% year-over-year, from 6.3× to 4.2×.
What is the long-term trend for Journey Medical Corporation's price / book?: Over 4 years (2021 to 2025), Journey Medical Corporation's price / book has grown at a 31.2% compound annual growth rate (CAGR), from 2.2× to 6.6×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.